Key result
Tirzepatide use linked to pulmonary embolism in one patient with type 2 diabetes.
Why the study?
Recent case reports have linked tirzepatide to venous thromboembolism events, especially during significant weight loss, raising safety concerns.
Does tirzepatide increase the risk of pulmonary embolism in patients with type 2 diabetes mellitus and obesity?
Case Report (n=1)
Does tirzepatide increase the risk of pulmonary embolism in patients with type 2 diabetes mellitus and obesity?
This case report highlights a potential safety signal of pulmonary embolism associated with tirzepatide use, emphasizing the need for further research on its thromboembolic risks.
Supports hypothesis generation on tirzepatide's VTE effects in T2DM; leaves open confirmation in randomized trials.
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a prevalent condition with a significant annual incidence, particularly increasing with age. Its pathophysiology is explained by Virchow’s triad (venous stasis, vascular injury, and hypercoagulability). Tirzepatide, a dual receptor agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), is approved for type 2 diabetes mellitus (T2DM) and obesity, showing efficacy in lowering HbA1c and promoting weight loss. Recent case reports have linked tirzepatide to VTE events, particularly in patients experiencing significant weight loss, raising concerns about its safety profile. We present a case of a male T2DM subject who developed PE after five injections of tirzepatide in a patient with grade I obesity. We also review emerging literature on VTE associated with tirzepatide, emphasizing the need for further research to clarify the drug’s risk and underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Arecco et al. (2026) conducted a case report in Type 2 diabetes mellitus and grade I obesity (n=1). Tirzepatide was evaluated on Pulmonary embolism. Tirzepatide administration was associated with the development of pulmonary embolism in 1 male patient with type 2 diabetes and grade I obesity after receiving 5 injections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: